Shmuel Rubinstein - Kamada Director
| KMDA Stock | USD 5.05 0.05 0.98% |
Director
Mr. Shmuel Rubinstein was appointed Director of the Company., effective on November 30, 2017. Mr. Rubinstein served as Chief Executive Officer of Taro Pharmaceuticals from 1990 to 2010. During this time, the company grew from 10 million in revenue to over 400 million. He currently serves on the boards of multiple public and private biopharmaceutical companies, including Clal Biotechnology and Exalenz Bioscience Ltd. since 2017.
| Age | 78 |
| Tenure | 7 years |
| Address | 2 Holzman Street, Rehovot, Israel, 7670402 |
| Phone | 972 8 940 6472 |
| Web | https://www.kamada.com |
Kamada Management Efficiency
The company has return on total asset (ROA) of 0.0186 % which means that it generated a profit of $0.0186 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0394 %, meaning that it created $0.0394 on every $100 dollars invested by stockholders. Kamada's management efficiency ratios could be used to measure how well Kamada manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Tangible Assets is expected to grow to 0.04. The current year's Return On Capital Employed is expected to grow to 0.04. At present, Kamada's Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 192.6 M, whereas Non Currrent Assets Other are forecasted to decline to about 480.5 K.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Anupam Puri | Dr Reddys Laboratories | 69 | |
| Gary Kunkle | Perrigo Company PLC | 67 | |
| Andreas Wicki | Pacira Pharmaceuticals | 59 | |
| Adriana Karaboutis | Perrigo Company PLC | 58 | |
| Robert Glenning | Eagle Pharmaceuticals | 57 | |
| Scott LLB | Lucy Scientific Discovery | 54 | |
| Marla Kessler | Ironwood Pharmaceuticals | 48 | |
| Bruce Carter | Dr Reddys Laboratories | 77 | |
| Susan Kelley | Deciphera Pharmaceuticals LLC | 63 | |
| John Freund | Collegium Pharmaceutical | 64 | |
| Garen Bohlin | Collegium Pharmaceutical | 70 | |
| Thomas Penn | ANI Pharmaceuticals | 72 | |
| Gary Pace | Pacira Pharmaceuticals | 70 | |
| Carol Wrenn | Phibro Animal Health | 57 | |
| J Moreau | Dr Reddys Laboratories | 64 | |
| Theodore Samuels | Perrigo Company PLC | 66 | |
| Thomas Lawrence | Cumberland Pharmaceuticals | 74 | |
| Mark Brooks | Alimera Sciences | 50 | |
| Daniel Raynor | ANI Pharmaceuticals | 56 | |
| Liam Ratcliffe | Deciphera Pharmaceuticals LLC | 53 | |
| John Snisarenko | Alimera Sciences | N/A | |
Management Performance
| Return On Equity | 0.0394 | ||||
| Return On Asset | 0.0186 |
Kamada Leadership Team
Elected by the shareholders, the Kamada's board of directors comprises two types of representatives: Kamada inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Kamada. The board's role is to monitor Kamada's management team and ensure that shareholders' interests are well served. Kamada's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Kamada's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Pnina Strauss, VP of Clinical Devel. and IP | ||
| Itzhak Krinsky, Director | ||
| Boris Gorelik, Vice Programs | ||
| Barak Bashari, Sr. VP of Operations | ||
| Eran Schenker, Vice President - Medical Director | ||
| Tuvia Shoham, Director | ||
| Eran Nir, Chief Officer | ||
| Hanni Neheman, Vice Sales | ||
| Shavit Beladev, Vice Plasma | ||
| Michal Stein, Vice President and Medical Director for Immunology | ||
| Ariella Raban, VP HR | ||
| Shani Dotan, Vice President of Human Resources | ||
| Liliana Bar, VP of RandD | ||
| Yael Brenner, Vice President - Quality | ||
| LLB BA, General VP | ||
| Abraham Havron, External Director | ||
| Asaf Frumerman, Director | ||
| Ruth Wolfson, Sr. VP of Scientific Affairs | ||
| Shmuel Rubinstein, Director | ||
| Naveh Tov, Vice President-Clinical Development and Medical Director for Pulmonary Diseases | ||
| Jon Knight, Vice Operations | ||
| Michael Berelowitz, Director | ||
| David Tsur, Co-Founder and Deputy Executive Chairman | ||
| Orit Pinchuk, Vice President - Regulatory Affairs and Quality R&D | ||
| Leon Recanati, Director | ||
| Liron Reshef, Vice Resources | ||
| Gil Efron, CFO, Principal Accounting Officer and Deputy CEO | ||
| Jonathan Hahn, Director | ||
| Eran Schenkar, Vice President - Medical Director | ||
| Gwen Melincoff, Director | ||
| Chaime Orlev, Chief Officer | ||
| Michal Ayalon, Vice President - Research & Development | ||
| Yifat Esq, Gen Legal | ||
| Amir London, Chief Officer | ||
| Estery GilozRan, Independent Director | ||
| Reuven Behar, Director | ||
| Eitan Kyiet, Vice President - Business Development | ||
| Ziv Kop, Director |
Kamada Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Kamada a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0394 | ||||
| Return On Asset | 0.0186 | ||||
| Profit Margin | 0.06 % | ||||
| Operating Margin | 0.08 % | ||||
| Current Valuation | 246.33 M | ||||
| Shares Outstanding | 57.48 M | ||||
| Shares Owned By Insiders | 7.31 % | ||||
| Shares Owned By Institutions | 49.36 % | ||||
| Number Of Shares Shorted | 40.25 K | ||||
| Price To Earning | 11.71 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Kamada. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in unemployment. For information on how to trade Kamada Stock refer to our How to Trade Kamada Stock guide.Note that the Kamada information on this page should be used as a complementary analysis to other Kamada's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.
Complementary Tools for Kamada Stock analysis
When running Kamada's price analysis, check to measure Kamada's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kamada is operating at the current time. Most of Kamada's value examination focuses on studying past and present price action to predict the probability of Kamada's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kamada's price. Additionally, you may evaluate how the addition of Kamada to your portfolios can decrease your overall portfolio volatility.
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories |
Is Kamada's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Kamada. If investors know Kamada will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Kamada listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.227 | Earnings Share 0.15 | Revenue Per Share 2.919 | Quarterly Revenue Growth (0.20) | Return On Assets 0.0186 |
The market value of Kamada is measured differently than its book value, which is the value of Kamada that is recorded on the company's balance sheet. Investors also form their own opinion of Kamada's value that differs from its market value or its book value, called intrinsic value, which is Kamada's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kamada's market value can be influenced by many factors that don't directly affect Kamada's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Kamada's value and its price as these two are different measures arrived at by different means. Investors typically determine if Kamada is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kamada's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.